EphB4 Regulates the Growth and Migration of Pancreatic Cancer Cells

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2014 Jul 24

PMID 25051915

Citations 4

Authors

Man Li

Jinbo Zhao

Jinjing Qiao

Chen Song

Zuowei Zhao

Affiliations

Soon will be listed here.

Abstract

Pancreatic cancer is a serious threat to human life. Moreover, its treatment is complicated and its prognosis is very poor. Therefore, a new method for the diagnosis and treatment of pancreatic cancer is very essential. In this study, a eukaryotic expression plasmid targeting EphB4 was constructed and transfected into PANC-1 pancreatic cancer cells to investigate the inhibition of cell growth and the progression of iRNA against EphB4. This study provides the basis for the gene therapy of pancreatic cancer. The recombinant eukaryotic EphB4 expression plasmid, pSIREN-RetroQ-ZsGreen-EphB4 and a negative control plasmid, pSIREN-RetroQ-ZsGreen-N, were constructed. At 48 h after transfection, the relative messenger RNA (mRNA) and protein levels of EphB4 were measured by RT-PCR and western blot. The proliferation of the transfected cells was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, while cell migration ability was analyzed using the scratch migration assay. At 48 h after transient transfection, EphB4 mRNA expression was significantly decreased in transfected PANC-1 cells as compared to the control group (P < 0.01). In vitro, inhibition of EphB4 expression weakened the proliferation and cell migration ability of PANC-1 cells compared to the control group. The small interfering RNA (siRNA) eukaryotic expression plasmid vector targeting EphB4 was successfully constructed and effectively transfected into PANC-1 cells. The recombinant plasmid can inhibit the expression of EphB4 mRNA and protein in PANC-1 cells, as well as cell growth and migration.

Citing Articles

Identification of 68 HLA-A24 and -A2-restricted cytotoxic T lymphocyte-inducing peptides derived from 10 common cancer-specific antigens frequently expressed in various solid cancers.

Kinoshita H, Takenouchi K, Tsukamoto N, Ohnuki K, Suzuki T, Nakatsura T Neoplasia. 2025; 61:101135.

PMID: 39938154 PMC: 11869973. DOI: 10.1016/j.neo.2025.101135.

Tyrosine Phosphoproteomics of Patient-Derived Xenografts Reveals Ephrin Type-B Receptor 4 Tyrosine Kinase as a Therapeutic Target in Pancreatic Cancer.

Renuse S, Madamsetty V, Mun D, Madugundu A, Singh S, Udainiya S Cancers (Basel). 2021; 13(14).

PMID: 34298619 PMC: 8303779. DOI: 10.3390/cancers13143404.

Cell-Free RNA Content in Peripheral Blood as Potential Biomarkers for Detecting Circulating Tumor Cells in Non-Small Cell Lung Carcinoma.

Yu X, Wu Y, Liu X, Huang X, Hou X, Wang J Int J Mol Sci. 2016; 17(11).

PMID: 27827952 PMC: 5133845. DOI: 10.3390/ijms17111845.

Periostin: A Downstream Mediator of EphB4-Induced Osteogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells.

Zhang F, Zhang Z, Sun D, Dong S, Xu J, Dai F Stem Cells Int. 2016; 2016:7241829.

PMID: 26788070 PMC: 4695675. DOI: 10.1155/2016/7241829.

The lymphatic system and pancreatic cancer.

Fink D, Steele M, Hollingsworth M Cancer Lett. 2016; 381(1):217-36.

PMID: 26742462 PMC: 4969225. DOI: 10.1016/j.canlet.2015.11.048.

References

Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C . Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009; 52(20):6433-46. DOI: 10.1021/jm9009444. View

Wu Q, Suo Z, Kristensen G, Baekelandt M, Nesland J . The prognostic impact of EphB2/B4 expression on patients with advanced ovarian carcinoma. Gynecol Oncol. 2006; 102(1):15-21. DOI: 10.1016/j.ygyno.2005.11.034. View

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

Xia G, Kumar S, Masood R, Zhu S, Reddy R, Krasnoperov V . EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005; 65(11):4623-32. DOI: 10.1158/0008-5472.CAN-04-2667. View

Testa J, Bellacosa A . AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A. 2001; 98(20):10983-5. PMC: 58668. DOI: 10.1073/pnas.211430998. View

Xia G, Kumar S, Masood R, Koss M, Templeman C, Quinn D . Up-regulation of EphB4 in mesothelioma and its biological significance. Clin Cancer Res. 2005; 11(12):4305-15. DOI: 10.1158/1078-0432.CCR-04-2109. View

Scehnet J, Ley E, Krasnoperov V, Liu R, Manchanda P, Sjoberg E . The role of Ephs, Ephrins, and growth factors in Kaposi sarcoma and implications of EphrinB2 blockade. Blood. 2008; 113(1):254-63. PMC: 2614637. DOI: 10.1182/blood-2008-02-140020. View

Alam S, Fujimoto J, Jahan I, Sato E, Tamaya T . Coexpression of EphB4 and ephrinB2 in tumour advancement of ovarian cancers. Br J Cancer. 2008; 98(4):845-51. PMC: 2259170. DOI: 10.1038/sj.bjc.6604216. View

Astin J, Batson J, Kadir S, Charlet J, Persad R, Gillatt D . Competition amongst Eph receptors regulates contact inhibition of locomotion and invasiveness in prostate cancer cells. Nat Cell Biol. 2010; 12(12):1194-204. DOI: 10.1038/ncb2122. View

10.

Steinle J, Meininger C, Forough R, Wu G, Wu M, Granger H . Eph B4 receptor signaling mediates endothelial cell migration and proliferation via the phosphatidylinositol 3-kinase pathway. J Biol Chem. 2002; 277(46):43830-5. DOI: 10.1074/jbc.M207221200. View

11.

Pasquale E . Eph-ephrin promiscuity is now crystal clear. Nat Neurosci. 2004; 7(5):417-8. DOI: 10.1038/nn0504-417. View

12.

Xia G, Kumar S, Stein J, Singh J, Krasnoperov V, Zhu S . EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival. Oncogene. 2005; 25(5):769-80. DOI: 10.1038/sj.onc.1209108. View

13.

Noren N, Lu M, Freeman A, Koolpe M, Pasquale E . Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci U S A. 2004; 101(15):5583-8. PMC: 397426. DOI: 10.1073/pnas.0401381101. View

14.

Sinha U, Kundra A, Scalia P, Smith D, Parsa B, Masood R . Expression of EphB4 in head and neck squamous cell carcinoma. Ear Nose Throat J. 2003; 82(11):866, 869-70, 887. View

15.

Kumar S, Singh J, Xia G, Krasnoperov V, Hassanieh L, Ley E . Receptor tyrosine kinase EphB4 is a survival factor in breast cancer. Am J Pathol. 2006; 169(1):279-93. PMC: 1698769. DOI: 10.2353/ajpath.2006.050889. View

16.

Liu S, Li D, Park R, Liu R, Xia Z, Guo J . PET imaging of colorectal and breast cancer by targeting EphB4 receptor with 64Cu-labeled hAb47 and hAb131 antibodies. J Nucl Med. 2013; 54(7):1094-100. DOI: 10.2967/jnumed.112.116822. View

17.

Kumar S, Masood R, Spannuth W, Singh J, Scehnet J, Kleiber G . The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br J Cancer. 2007; 96(7):1083-91. PMC: 2360128. DOI: 10.1038/sj.bjc.6603642. View

18.

Flanagan J, Vanderhaeghen P . The ephrins and Eph receptors in neural development. Annu Rev Neurosci. 1998; 21:309-45. DOI: 10.1146/annurev.neuro.21.1.309. View

19.

Al-Haddad M, Martin J, Nguyen J, Pungpapong S, Raimondo M, Woodward T . Vascular resection and reconstruction for pancreatic malignancy: a single center survival study. J Gastrointest Surg. 2007; 11(9):1168-74. DOI: 10.1007/s11605-007-0216-x. View

20.

Gerety S, Anderson D . Cardiovascular ephrinB2 function is essential for embryonic angiogenesis. Development. 2002; 129(6):1397-410. DOI: 10.1242/dev.129.6.1397. View